Exelixis (EXEL) Change in Account Payables (2016 - 2026)
Exelixis (EXEL) posted quarterly Change in Account Payables of -$17.9 million for Q2 2026, down 310.53% year-over-year from $8.5 million in Q2 2025, and down 38.74% quarter-over-quarter from -$12.9 million in Q1 2026.
Analysis
Exelixis (EXEL) Change in Account Payables (2016 - 2026) Analysis & Trends
Exelixis' Change in Account Payables history runs 11 years deep, the most recent figure standing at -$17.9 million for Q2 2026.
- In Q2 2026, Change in Account Payables fell 310.53% year-over-year to -$17.9 million; the TTM figure through Apr 2026 stood at -$76.6 million (down 466.94% YoY), while the FY2026 annual figure was -$50.2 million, down 129.15% from the prior year.
- Change in Account Payables for Q2 2026 stood at -$17.9 million, down from -$12.9 million in the prior quarter.
- The five-year high for Change in Account Payables was $43.6 million in Q4 2023, with the low at -$63.5 million in Q3 2025.
- The 5-year median for Change in Account Payables is $2.2 million (2025), against an average of -$968823.5.
- Peak annual rise in Change in Account Payables reached 3481.14% in 2024, while the deepest fall reached 8332.45% in 2024.
- Exelixis' Change in Account Payables stood at $19.8 million in 2022, then soared by 120.68% to $43.6 million in 2023, then tumbled by 39.52% to $26.4 million in 2024, then slumped by 32.73% to $17.8 million in 2025, then slumped by 200.8% to -$17.9 million in 2026.
- Business Quant data shows EXEL's Change in Account Payables at -$17.9 million in Q2 2026, -$12.9 million in Q1 2026, and $17.8 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -8.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 5.03 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 37.53 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Exelixis | 14.81 Bn | 13.97 Bn | 608.03 Mn | 5.03 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 3, 2026 | 5.03 Mn |
| Apr 3, 2026 | -17.90 Mn |
| Jan 2, 2026 | -12.90 Mn |
| Oct 3, 2025 | 17.76 Mn |
| Jul 4, 2025 | -63.51 Mn |
| Apr 4, 2025 | 8.50 Mn |
| Jan 3, 2025 | 2.24 Mn |
| Sep 27, 2024 | 26.39 Mn |
| Jun 28, 2024 | -16.28 Mn |
| Mar 29, 2024 | -34.25 Mn |
| Dec 29, 2023 | 43.64 Mn |
| Sep 29, 2023 | 737,000.00 |
| Jun 30, 2023 | 5.32 Mn |
| Mar 31, 2023 | 416,000.00 |
| Dec 30, 2022 | 19.77 Mn |
| Sep 30, 2022 | -14.32 Mn |
| Jul 1, 2022 | 10.53 Mn |
| Apr 1, 2022 | 7.38 Mn |
| Dec 31, 2021 | 21.23 Mn |
| Oct 1, 2021 | 8.00 Mn |